For the Inventor, By the Inventor

Enter assignee name

Ann Arbor, MI, United States of America

Esperion Therapeutics, Inc.

USPTO Granted Patents = 60

% Expired Patents = 28.3

CIPO Patents = 3

EPO Patents = 10

Trademarks = 3

Forward Citations = 1,340

Loading Chart...

Loading Chart...

48 inventors (with patents filed for the assignee):

Carmen Daniela Oniciu (30 out of 31 patents)

Jean-Louis Henri Dasseux (29 out of 33 patents)

Jean-Louis Henri Dasseux (13 out of 59 patents)

4. Richard Copp (8 out of 8 patents)

5. Mohamed Abdelnasser (8 out of 8 patents)

6. Christopher M Cimarusti (8 out of 9 patents)

7. Jonathan Lane (7 out of 8 patents)

8. Michael Barkman (7 out of 7 patents)

9. Rasidul Amin (7 out of 8 patents)

10. Arthur John Cooper (7 out of 8 patents)

11. Damodaragounder Gopal (7 out of 14 patents)

12. Philipp Selig (7 out of 8 patents)

13. Roger Schofield Newton (5 out of 11 patents)

14. Daniela Carmen Oniciu (3 out of 16 patents)

15. Hans Ageland (3 out of 7 patents)

Core Competencies:

Bempedoic Acid

Cholesterol Management

Cardiovascular Disease

Fixed Dose Combinations

Apolipoprotein

Ketone Compounds

Hydroxyl Compounds

Ether Compounds

Dihydroxyl Compounds

Fourier Transform Mass Spectrometry

Synthesis Intermediates

Peptide/Lipid Complexes

60 patents: Sort by Forward Citations

1. 12404227 - Methods of making bempedoic acid and compositions of the same (2025-09-02),

2. 12398087 - Methods of making bempedoic acid and compositions of the same (2025-08-26),

3. 12344578 - Salt forms of bempedoic acid and methods for using the same (2025-07-01),

4. 11987548 - Methods of making bempedoic acid and compositions of the same (2024-05-21),

5. 11926584 - Methods of making bempedoic acid and compositions of the same (2024-03-12),

6. 11760714 - Methods of making bempedoic acid and compositions of the same (2023-09-19),

7. 11744816 - Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease (2023-09-05),

8. 11613511 - Methods of making bempedoic acid and compositions of the same (2023-03-28),

9. 11407705 - Methods of making bempedoic acid and compositions of the same (2022-08-09),

10. 10941095 - Hydroxyl compounds and compositions for cholesterol management and related uses (2021-03-09),

11. 10912751 - Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease (2021-02-09),

12. 10118881 - Hydroxyl compounds and compositions for cholesterol management and related uses (2018-11-06),

13. 10047028 - Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses (2018-08-14),

14. 9624152 - Hydroxyl compounds and compositions for cholesterol management and related uses (2017-04-18),

15. 9610324 - Apolipoprotein mixtures (2017-04-04),

Company Overview

Esperion Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies for cholesterol management and cardiovascular disease. The company specializes in bempedoic acid and fixed-dose combinations aimed at reducing cholesterol levels and improving heart health. Esperion's research encompasses various core technology topics, including apolipoproteins and ketone compounds, positioning it as a key player in the field of cardiovascular therapeutics.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

60 Patents

#11 in Ann Arbor, MI

#236 in Michigan

#5,992 in US

#12,083 in the World

Ann Arbor, MI, United States of America

Esperion Therapeutics, Inc.

Forward Citations = 1,340

48 inventors:

Carmen Daniela Oniciu (30 out of 31 patents)

Jean-Louis Henri Dasseux (29 out of 33 patents)

Jean-Louis Henri Dasseux (13 out of 59 patents)

4. Richard Copp (8 out of 8 patents)

5. Mohamed Abdelnasser (8 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Esperion Therapeutics, Inc.. Retrieved from https://idiyas.com/company/esperion-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…